Back to News
News

PT-141 (Bremelanotide): What the Research Shows

06 April 2026By Pure Chems Research Team 1 min read
PT-141 (Bremelanotide): What the Research Shows

Research Use Only: This article summarises published scientific literature for laboratory and research audiences. It is not medical advice, and PT-141 is not approved for human or veterinary use in this context.

What is PT-141?

PT-141 (Bremelanotide) is a synthetic cyclic peptide studied in the research literature as a melanocortin receptor agonist, with particular activity at the MC4 receptor. It is a metabolite-related analogue of an earlier melanocortin peptide and is a common subject in laboratory receptor-signalling studies.

Where PT-141 sits in the research literature

The evidence base includes cell and animal studies of melanocortin-receptor signalling, as well as clinical research. Any findings from these models should be interpreted within their research context.

Reported areas of preclinical interest

  • MC4 receptor agonism: studied for central melanocortin-pathway signalling in laboratory models.
  • Neuroendocrine pathways: examined within melanocortin-system research.

Why the “research use only” label matters

The PT-141 supplied here is a research material and is intended strictly for laboratory and scientific research, not for human or veterinary consumption.

Handling and storage

Store lyophilised peptide cool, dry and away from light, and refrigerate reconstituted solution, using it within the indicated stability window. Follow the documentation supplied with each batch.

Frequently asked questions

What does PT-141 do in research?

It is studied as a melanocortin receptor agonist, notably at MC4R, in laboratory signalling models.

Is PT-141 approved for human use?

The material supplied here is a research chemical only and is not intended for human or veterinary use.

Key takeaways

PT-141 (Bremelanotide) is a melanocortin receptor agonist studied in preclinical signalling research. It is a research material only. Review the PT-141 research product.

References

References sourced via PubMed.

  1. Dhillon S, Keam SJ. Bremelanotide: first approval. Drugs. 2019;79(14):1599-1606. DOI · PubMed 31429064.

Disclaimer: This article is for informational and educational purposes for a research audience. It is not medical advice. Products referenced are sold strictly for laboratory research and are not for human or veterinary use.

Research-grade compounds, verified purity

Every batch ships with a Certificate of Analysis. Explore the full PureChems catalog.

Browse the catalog